hsa-miR-485-5p reverses epithelial to mesenchymal transition and promotes cisplatin-induced cell death by targeting PAK1 in oral tongue squamous cell carcinoma

XIU-JUAN LIN¹,²*, CHANG-LI HE²*, TING SUN³, XUE-JING DUAN⁴, YI SUN⁵ and SHI-JIANG XIONG¹

¹Department of VIP Center and Shandong Provincial Key Laboratory of Oral Biomedicine, School and Hospital of Stomatology, Shandong University, Jinan, Shandong 250012; ²Department of Stomatology, Qianfoshan Hospital Affiliated to Shandong University, Jinan, Shandong 250014; ³Department of Stomatology, Yidu Central Hospital of Weifang, Weifang, Shandong 262500; ⁴Department of Stomatology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021; ⁵Department of Special Clinic, Weifang Stomatological Hospital, Weifang, Shandong 261021, P.R. China

Received August 1, 2016; Accepted April 7, 2017

DOI: 10.3892/ijmm.2017.2992

Abstract. Oral squamous cell carcinoma (OSCC) is currently a highly prevalent disease worldwide. Cisplatin (CDDP) is widely used for the chemotherapy of OSCC. Yet, the molecular mechanisms responsible for cisplatin resistance have not been fully elucidated. In this study, we showed that overexpression of p21 (RAC1) activated kinase 1 (PAK1) induced epithelial to mesenchymal transition (EMT) and significantly promoted the invasion and migration of oral squamous cell carcinoma SCC25 cells. Emerging evidence indicates a strong link between resistance to therapy and the induction of EMT in cancer. We showed that overexpression of PAK1 induced cisplatin resistance in SCC25 cells. ERCC1 and YAP can promote cisplatin resistance in human OSCC. We showed that ERCC1 and YAP protein were upregulated by PAK1 in SCC25 cells. We found that miR-485-5p inhibited PAK1 protein expression in the SCC25 cells. Contrary to PAK1, we demonstrated that overexpression of miR-485-5p reversed EMT and significantly inhibited invasion and migration. Moreover, its overexpression sensitized SCC25-CR cells (cisplatin-resistant cells) to cisplatin. Thus, we conclude that miR-485-5p reverses EMT and promotes cisplatin-induced cell death by targeting PAK1 in oral tongue squamous cell carcinoma. This study suggests that PAK1 plays an essential role in the progression of OSCC and it is a potential therapeutic target for OSCC.

Introduction

Oral squamous cell carcinoma (OSCC) is currently a highly prevalent disease worldwide (1). More than half of patients die of this disease or the associated complications within 5 years even under available therapies (2). The prognosis of OSCC remains dismal (2). The low median survival rate is associated with chemotherapeutic resistance (3,4). Presently, there is limited information regarding the regulatory mechanisms of chemoresistance in oral cancer.

Epithelial to mesenchymal transition (EMT) is an essential process for driving plasticity during development and in the context of different morphogenetic events; however it is also an unintentional behavior of cells during malignant transformation (5-6). During this process, the cells lose their epithelial characteristics, including their polarity and specialized cell-cell contacts, and acquire a migratory behavior, allowing them to move away from their epithelial cell community and to integrate into surrounding tissue, even at remote locations. EMT illustrates the differentiation plasticity during development and is complemented by another process, called mesenchymal to epithelial transition (MET) (8). Emerging evidence suggests that there is a strong link between therapeutic resistance and the induction of EMT in cancer (9). Identifying the mechanisms that promote EMT and the development of drug resistance could be a key approach for the development of novel therapeutic targets.

p21 (RAC1) activated kinase 1 (PAK1) lies within the 11q13 region. Aberrant expression/activation of PAK1 has been described in OSCC as well as in several other types of cancers including breast, brain, pancreatic, colon, bladder, ovarian, hepatocellular, urinary tract, renal cell carcinoma and thyroid cancers (10). Stimulating OSCC cells with serum growth factors was found to lead to PAK1 re-localization and caused profound cytoskeletal remodeling (11). PAK1 was also found to be involved in the invasion, migration and cytoskeletal remodelling for OSCC cells (11). In this study, we showed that PAK1 could be a potential therapeutic target for OSCC.

*Contributed equally

Key words: oral squamous cell carcinoma, cisplatin resistance, miR-485-5p, p21 (RAC1) activated kinase 1
Materials and methods

Human OSCC cell lines, SCC25 and SCC25-res (cisplatin-resistant cells). SCC25 cells were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). To obtain cisplatin-resistant tongue cancer cells, we treated SCC25 cells with escalating concentrations of cisplatin from 10<sup>2</sup> to 10<sup>3</sup> M. The established SCC25-res (cisplatin-resistant SCC25) cells grew at a similar rate in the presence or absence of 10<sup>3</sup> M cisplatin for 3 days (data not shown). The IC<sub>50</sub> is the cisplatin concentration that reduces proliferating cells by 50%. The IC<sub>50</sub> of SCC25-res cells increased by 12-fold, respectively, as compared with the SCC25 cells (data not shown). All cancerous cell lines were grown in RPMI-1640 medium (Thermo Scientific, Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS) (HyClone, Rockford, IL, USA) and 100 U/ml penicillin and streptomycin.

**MTT assay.** Cell proliferation was assessed by 3-(4,5-‐dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) assay (Sigma, St. Louis, MO, USA). MTT assay was performed as previously described (12-14). In brief, the cells were plated in 96-‐well plates in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum at a density of 8x10<sup>3</sup> cells per well at 37°C in a 5% CO<sub>2</sub> incubator for 4 h, and the supernatant was then removed and 20 µl of dimethyl sulfoxide were added to each well. Following incubation for 10 min, the absorbance of each well was measured using a Synergy™ 4 (BioTek Instruments, Winooski, VT, USA) at a wavelength of 570 nm, with the reference wavelength set at 630 nm. Absorbance was directly proportional to the number of surviving cells. The viability of the control group (cells transfected with pcDNA3.1) was considered to be 100%.

**BrdU incorporation assay.** Cell proliferation was also assessed using a colorimetric BrdU proliferation kit by following the manufacturer’s instructions (Cat. no. 11647229001; Roche; Basel, Switzerland). Briefly, the cells treated with the peptides were labeled with BrdU for 3 to 4 h. The genomic DNA was then fixed and denatured, followed by incubation with peroxidase-conjugated anti-BrdU antibody for 90 min. The substrate of the conjugated peroxidase was then added and the reaction product was measured by determining the absorbance (A370-A492 nm). The results were then normalized by the number of total viable cells, which was determined by a side-‐by-‐side cell viability assay as described above.

**PAK1-expressing plasmids/empty vectors and transfection experiments.** PAK1-expressing plasmids and empty vectors (pcDNA3.1) were obtained from Tiangen Biotech (Beijing, China). The cells were seeded at a density of 1.5x10<sup>5</sup> per well in 6-‐well plates or 60-‐mm dishes in 2 ml of complete medium containing 10% FCS for 24 h. Transfections were performed using Lipofectamine 2000 transfection reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's instructions.

**Western blot analysis.** The total proteins in cells were extracted with protein lysis solution (Tiangen Biotech). The protein concentration was measured with a bichinoninic acid kit (Tiangen Biotech). Protein extracts were resolved through 8% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-‐PAGE), transferred to polyvinylidene difluoride membranes (Bio-‐Rad, Berkeley, CA, USA), probed with antibodies against human ERCC1 (1:500; ab129267), YAP (1:500; ab52771), PKA (1:500; ab40795), vimentin (1:500; ab92547), E-‐cadherin (1:500; ab40772) or β-‐actin (1:500; ab8227) (all from Abcam, Cambridge, MA, USA) and then with IRDye™-‐800 conjugated anti-‐rabbit secondary antibodies (ab218695; Abcam) for 30 min at room temperature. The specific proteins were visualized by Odyssey™ Infrared Imaging System (Gene Company, Lincoln, NE, USA).

**Real-‐time PCR for microRNAs.** Total RNA from the cultured cells, with efficient recovery of small RNAs, was isolated using the mirVana miRNA isolation kit (Ambion, Austin, TX, USA). Detection of the mature form of miRNAs was performed using the mirVana qRT-‐PCR miRNA detection kit and qRT-‐PCR primer sets, according to the manufacturer's instructions (Ambion). The sequences of the primers were as follows: miR-‐485-‐5p forward, 5'-‐CCAAGCTTCCACCCATTCTAAACGGAC-‐3' and reverse, 5'-‐CGGGATCCGAGGTCTAGTGATCATC-‐3'. The U6 small nuclear RNA was used as an internal control.

**Immunofluorescence staining.** Cells were stained for immunofluorescence on coverslips. After fixation and permeabilization, the cells were incubated with primary antibodies against PAK1, E-‐cadherin or vimentin (Abcam) and then incubated with FITC-‐conjugated secondary antibodies (Invitrogen). The coverslips were counterstained with 4',6-‐diamidino-‐2-‐phenylindole (DAPI) and imaged under a confocal microscope TCS SP5 (Leica, Solms, Germany).

**Reverse transcription-‐PCR and real-‐time PCR for mRNA.** PCR was performed as previously described (12,15). The PCR primer sequences are as follows, glyceraldehyde 3-‐phosphate dehydrogenase (GAPDH) forward, 5’-‐ATTCACCGCCACAGTCAAAGG-‐3’ and reverse, 5’-‐GCCAGAAGGGCCGGAGA-‐3’; β-‐actin forward, 5’-‐TCACAGTCCTCGACGAACT-‐3’ and reverse, 5’-‐GCAGCTGACTTTCCTGAG-‐3’; vimentin forward, 5’-‐GACAATGCACCGCTGTGGG-‐3’ and reverse, 5’-‐CAGCTGTTTGCTGAGCAGG-‐3’; GAPDH forward, 5’-‐ATTCAACGGCACAGTCAAGG-‐3’ and reverse, 5’-‐GCCAACGACTTTCCATCGA-‐3’; E-‐cadherin forward, 5’-‐ATACGAGCCACGAGTC-‐3’ and reverse, 5’-‐GGTGAAACCCTACATCTGTGGG-‐3’. Absorbance was directly proportional to the number of surviving cells. The viability of the control group (cells transfected with pcDNA3.1) was considered to be 100%.

**Methods of bioinformatics.** The analysis of potential microRNA target sites was performed using the commonly used prediction algorithm, miRanda (http://www.microrna.org/).

**Migration and invasion assays.** Migration and invasion assays were performed as previously described (16). The migration and invasion assays were performed using 24 well Transwell chambers (8 µm; Corning Inc., Corning, NY, USA). For the migration assay, 1x10<sup>5</sup> cells suspended in 200 µl serum-‐free RPMI-‐1640 medium were seeded into the upper chamber of the Transwell invasion system, and 500 µl RPMI-‐1640 medium containing 10% FBS was added to the lower chamber. Following a 24-‐h incubation, cells on the upper surface of the membrane were scrubbed off, and the migrated cells were fixed with 95% ethanol and stained with 0.1% crystal violet.
The results demonstrated that PAK1 promoted EMT, migration and invasion in SCC25 cells. To further verify the role of PAK1 in EMT, we transfected SCC25 cells with PAK1-expressing plasmids. We then performed MTT assay to detect the proliferation of SCC25 cells transfected with PAK1-expressing plasmids or empty vectors. The results revealed that PAK1 did not affect the proliferation of SCC25 cells after 48 h of transfection (Fig. 1A). In addition, we performed BrdU incorporation assay to detect DNA synthesis in the cells transfectected with the empty vectors. The results showed that PAK1 protein was significantly increased by PAK1-expressing plasmids in the cells (Fig. 1B). To further show the effects of PAK1 on proliferation, we used the commonly used prediction algorithm, miRanda (http://www.microrna.org/microrna/home.do), to analyze the 3' untranslated region (3'UTR) of PAK1. A number of microRNAs were found by the algorithm. But we were interested in miR-485-5p, as it has been reported that miR-485-5p is a tumor-suppression gene that inhibits oncogene expression (~22 nucleotides) that negatively regulate protein-coding gene expression by targeting mRNA degradation or translation inhibition (18-20). To further confirm whether PAK1 is regulated by microRNAs, we used the commonly used prediction algorithm, miRanda. To determine whether PAK1 is regulated by miR-485-5p, we performed RT-PCR to detect vimentin and E-cadherin mRNA in the cells treated as indicated. The results showed that overexpression of PAK1 could transform SCC25 cells to SCC25-CR cells (Fig. 3A), suggesting that its overexpression promoted cisplatin resistance. We also performed western blot analysis to detect ERCC1 and YAP protein expression in SCC25 cells transfected with the PAK1-expressing plasmids and empty vectors. The results demonstrated that the levels of ERCC1 and YAP protein were increased by PAK1 (Fig. 3B). Overexpression of the PAK1 promotes cisplatin resistance in SCC25 cells. To further identify whether PAK1 affects cisplatin efficacy in SCC25 cells, we transfected the cells with PAK1-expressing plasmids. We then performed MTT assay in the SCC25 cells treated as indicated. The results showed that overexpression of PAK1 could transform SCC25 cells to SCC25-CR cells (Fig. 3A), suggesting that its overexpression promoted cisplatin resistance. We also performed western blot analysis to detect ERCC1 and YAP protein expression in SCC25 cells transfected with the PAK1-expressing plasmids and empty vectors. The results demonstrated that the levels of ERCC1 and YAP protein were increased by PAK1 (Fig. 3B). miR-485-5p inhibits PAK1 protein expression in SCC25 cells. Having demonstrated that overexpression of PAK1 promoted EMT, migration and invasion in SCC25 cells, we next studied the mechanisms regulating PAK1 expression in SCC25 cells. MicroRNAs (miRs) are a class of small noncoding RNAs (~22 nucleotides) that negatively regulate protein-coding gene expression by targeting mRNA degradation or translation inhibition (18-20). To further confirm whether PAK1 is regulated by microRNAs, we used the commonly used prediction algorithm, miRanda. To analyze the 3' untranslated region (3'UTR) of PAK1. A number of microRNAs were found by the algorithm. But we were interested in miR-485-5p, as it has been reported that miR-485-5p is a tumor-suppression gene that inhibits oncogene expression (21-24). Thus, we reasoned that miR-485-5p could downregulate PAK1 protein expression by targeting its 3'UTR in SCC25 cells. The target sites on the 3'UTR of PAK1 are shown in Fig. 4A. To investigate whether PAK1 can affect the proliferation of SCC25 cells, firstly using western blot analysis, we tested whether PAK1-expressing plasmids could cause stable expression of PAK1 protein in the SCC25 cells. The results showed that PAK1 protein was significantly increased by PAK1-expressing plasmids in the cells (Fig. 1A). In addition, we performed MTT assay to detect the proliferation of SCC25 cells transfected with the PAK1-expressing plasmids. The results showed that PAK1 did not affect the proliferation of the SCC25 cells after 48 h of transfection (Fig. 1B). To further show the effects of PAK1 on proliferation, we performed BrdU incorporation assay to detect DNA synthesis in the cells. The results confirmed that PAK1 did not affect DNA synthesis in the cells (Fig. 1C). microRNA (miR)-485-5p was detected and quantified using qPCR. The results showed that miR-485-5p was significantly upregulated in SCC25 cells transfected with PAK1-expressing plasmids when compared to the control (mock). A summary of the results is shown in Fig. 4B. To identify the role of miR-485-5p in regulating PAK1 expression in SCC25 cells, we transfected SCC25 cells with pre-miR-485-5p and control miR. After transfection, miR-485-5p expression was detected by real-time PCR and the results showed that miR-485-5p was significantly increased by pre-miR-485-5p in the cells (Fig. 4B). To confirm that miR-485-5p can regulate PAK1 expression, we performed western blot analysis to detect PAK1 protein expression in the SCC25 cells transfected with pre-miR-485-5p and control miR. The results showed that PAK1 protein was significantly inhibited by miR-485-5p (Fig. 4C). We next performed immunofluorescence analyses in SCC25 cells transfected with empty vectors. The number of migrated cells was determined by counting 5 random fields on each membrane. The invasion assay protocol was similar to that of the migration assay, with the exception that the upper chambers were first covered with 1 mg/ml Matrigel, as previously described (12,14,15,17).

Statistical analysis. Data are presented as the means ± SEM. Student's t-test (two-tailed) was used to compare two groups (P<0.05 was considered significant).

Results

PAK1 does not affect the proliferation of oral squamous cell carcinoma SCC25 cells. To investigate whether PAK1 can affect the proliferation of SCC25 cells, firstly using western blot analysis, we tested whether PAK1-expressing plasmids could cause stable expression of PAK1 protein in the SCC25 cells. The results showed that PAK1 protein was significantly increased by PAK1-expressing plasmids in the cells (Fig. 1A). In addition, we performed MTT assay to detect the proliferation of SCC25 cells transfected with the PAK1-expressing plasmids. The results showed that PAK1 did not affect the proliferation of the SCC25 cells after 48 h of transfection (Fig. 1B). To further show the effects of PAK1 on proliferation, we performed BrdU incorporation assay to detect DNA synthesis in the cells. The results confirmed that PAK1 did not affect DNA synthesis in the cells (Fig. 1C).
pre-miR-485-5p and control miR. The results showed that PAK1 protein was evidently inhibited in the cells transfected with pre-miR-485-5p (Fig. 4D).

miR-485-5p inhibits the proliferation of SCC25 cells. We performed MTT assay to detect the proliferation rate of the SCC25 cells transfected with miR-485-5p and control miR. The results demonstrated that miR-485-5p inhibited the proliferation of the SCC25 cells after 48 h of transfection (Fig. 5A).

To further show the effects of miR-485-5p on proliferation, we performed BrdU incorporation assay to detect DNA synthesis in the cells. The results confirmed that DNA synthesis of the cells was significantly inhibited (Fig. 5B).

miR-485-5p reverses EMT and inhibits the migration and invasion of SCC25 cells. To assess the role of miR-485-5p in EMT of SCC25 cells, we transfected SCC25 cells with pre-miR-485-5p and found that its overexpression caused significant changes in the cell morphology (MET, phenotype from a spindle-like morphology to a cobblestone-like) (Fig. 6A).

To further verify that the changes in cell morphology were caused by MET, we performed western blot analysis to detect the expression of epithelial marker, E-cadherin, and mesenchymal marker, vimentin, in the SCC25 cells transfected with pre-miR-485-5p and control miR. The results demonstrated that miR-485-5p inhibited vimentin protein expression and promoted E-cadherin protein expression (Fig. 6B).

We next sought to determine whether miR-485-5p has any impact on migration and invasion in the cells. The migration and invasion assays showed that overexpression of miR-485-5p inhibited the migration and invasion of cells transfected with pre-miR-485-5p (Fig. 6C).
Overexpression of miR-485-5p reverses cisplatin resistance in SCC25-CR (cisplatin-resistant cells) cells. To further identify whether miR-485-5p affects cisplatin efficacy in SCC25-CR cells, we transfected the cells with pre-miR-485-5p. We then performed MTT assay in the SCC25-CR cells treated as indicated (Fig. 7A). The results showed that overexpression of miR-485-5p transformed SCC25-CR cells to SCC25 cells, suggesting that its overexpression reversed cisplatin resistance. We also performed western blot analysis to detect ERCC1 and YAP protein expression in the SCC25 cells transfected with pre-miR-485-5p and control miR. The results demonstrated that levels of ERCC1 and YAP protein were decreased by miR-485-5p (Fig. 7B).
cisplatin resistance. It can block the oncogenic role of PAK1-mediated molecular mechanism is responsible for EMT and cisplatin-resistance in SCC25-CR cells. Thus, an miR-485-5p-mediated molecular reversal of EMT (34).

...the sensitivity to anticancer drugs could be re-established to anticancer drugs is confined to the ‘epithelial’ subset, and but we found that PAK1 did not inhibit the proliferation of 

...suppressor in gastric cancer, breast cancer, hepatocellular carcinoma and ovarian cancer, but its expression, cellular function and clinical features in OSCC are not known (21-24). Consistent with the roles of miR-485-5p in other cancers, we showed that its overexpression inhibited the proliferation of SCC25 cells. PAK1 is a target gene of miR-485-5p in SCC25. But we found that PAK1 did not inhibit the proliferation of SCC25 cells, implying that miR-485-5p inhibits proliferation by regulating other genes. It has been reported that sensitivity to anticancer drugs is confined to the ‘epithelial’ subset, and the sensitivity to anticancer drugs could be re-established by microRNA-mediated molecular reversal of EMT (34). Consistent with this report, we found that miR-485-5p reversed EMT and cisplatin-resistance in SCC25-CR cells. Thus, an miR-485-5p-mediated molecular mechanism is responsible for cisplatin resistance. It can block the oncogenic role of PAK1 and hence restoration of miR-485-5p has therapeutic potential in PAK1-positive OSCC.

References

1. Warnaokusariya S: Global epidemiology of oral and oropharyngeal cancer. Oral Oncol 45: 309-316, 2009.
2. Lo WL, Kao SY, Chi LY, Wong YK and Chang RC: Outcomes of oral squamous cell carcinoma in Taiwan after surgical therapy: Factors affecting survival. J Oral Maxillofac Surg 61: 751-758, 2003.
3. Pérez-Sayáns M, Somoza-Martín JM, Barros-Angueira F, Diz PG, Rey JM and García-García A: Multidrug resistance in oral squamous cell carcinoma: the role of vascular ATPases. Cancer Lett 295: 135-143, 2010.
4. Zhang Q, Shi S, Yen Y, Brown J, Ta JQ and Le AD: A subpopulation of CD133(+) cancer stem-like cells characterized in human oral squamous cell carcinoma confer resistance to chemotherapy. Cancer Lett 289: 151-160, 2010.
5. Nieto MA: The ins and outs of the epithelial to mesenchymal transition in health and disease. Annu Rev Cell Dev Biol 27: 347-376, 2011.
6. Savagner P, Yamada KM and Thiery JP: The zinc-finger protein slug causes desmosome dissociation, an initial and necessary step for growth factor-induced epithelial-mesenchymal transition. J Cell Biol 137: 1403-1419, 1997.
7. Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2: 442-454, 2002.
8. Polak K and Weinberg RA: Transitions between epithelial and mesenchymal states: Acquisition of malignant and stem cell traits. Nat Rev Cancer 9: 265-273, 2009.
9. Thiery JP, Acloque H, Huang NY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell 139: 871-890, 2009.
10. Kumar R, Gururaj AE and Barnes CF: p21-activated kinases in cancer. Nat Rev Cancer 6: 459-471, 2006.
11. Farvathy M, Sreeja S, Kumar R and Pillai MR: Potential role of p21 activated kinase 1 (PAK1) in the invasion and motility of oral cancer cells. BMC Cancer 16 (Suppl 1): 293, 2016.
12. Liao XH, Lu DL, Wang N, Liu LY, Wang Y, Li YQ, Yan TB, Sun XG, Hu P and Zhang TC: Estrogen receptor α mediates proliferation of breast cancer MCF-7 cells via a p21/PCNA/E2F1-dependent pathway. FEBS J 281: 927-942, 2014.
13. Li H, Xiang Y, Fan LJ, Zhang XY, Li JP, Yu CX, Bao LY, Cao DS, Xing WB, Liao XH and Zhang TC: Myocardin inhibited the gap protein connexin 43 via promoted miR-206 to regulate vascular smooth muscle cell phenotypic switch. Gene 616: 22-30, 2017.
14. Liao XH, Xiang Y, Yu CX, Li JP, Li H, Nie Q, Hu P, Zhou J and Zhang TC: STAT3 is required for MiR-17-5p-mediated sensitization to chemotherapy-induced apoptosis in breast cancer cells. Oncotarget 8: 15763-15774, 2017.
15. Xiang Y, Lu DL, Li JP, Yu CX, Zheng DL, Huang X, Wang ZY, Hu P, Liao XH and Zhang TC: Myocardin inhibits estrogen receptor alpha-mediated proliferation of human breast cancer MCF-7 cells via regulating MicroRNA expression. IUBMB Life 68: 477-487, 2016.
16. Lu Y, Chopp M, Zheng X, Katakowski M, Buller B and Jiang F: MiR-145 reduces ADAM17 expression and inhibits in vitro migration and invasion of glioma cells. Oncol Rep 29: 67-72, 2013.
17. Liao XH, Zheng LG, He HP, Zheng DL, Wei ZQ, Wang N, Dong J, Ma WJ and Zhang TC: STAT3 regulated ATR via microRNA-383 to control DNA damage to affect apoptosis in A431 cells. Cell Signal 22: 2285-2295, 2010.
18. Yoshikawa K, Noguchi K, Nakano Y, Yamamura M, Takaoka K, Hishimoto-Tamaoki T and Kishimoto H: The Hippo pathway transcriptional co-activator, YAP, confers resistance to cisplatin in human oral squamous cell carcinoma. Int J Oncol 46: 2364-2370, 2015.
19. Lee RC, Feinbaum RL and Ambros V: The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75: 843-854, 1993.
20. Pasquinelli AE, Reinhart BJ, Slack F, Martindale MQ, Kuroda MI, Maller B, Hayward DC, Ball EE, Degnan B, Müller P, et al: Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature 408: 86-89, 2000.
21. Kang M, Ren MP, Zhao L, Li CP and Deng MM: miR-485-5p acts as a negative regulator in gastric cancer progression by targeting flotillin-1. Am J Transl Res 7: 2212-2222, 2015.
22. Zhou J, Wang N, Zhang Y, Sun XG, Liao XH and Zhang TC: Myocardin inhibited the gap protein connexin 43 via promoted miR-206 to regulate vascular smooth muscle cell phenotypic switch. Gene 616: 22-30, 2017.
22. Jing LL and Mo XM: Reduced miR-485-5p expression predicts poor prognosis in patients with gastric cancer. Eur Rev Med Pharmacol Sci 20: 1516-1520, 2016.

23. Kim TH, Kim YK, Kwon Y, Heo HJ, Kang H, Kim G and An HJ: Deregulation of miR-519a, 153, and 485-5p and its clinicopathological relevance in ovarian epithelial tumours. Histopathology 57: 734-743, 2010.

24. Lou C, Xiao M, Cheng S, Lu X, Jia S, Ren Y and Li Z: MiR-485-3p and miR-485-5p suppress breast cancer cell metastasis by inhibiting PGC-1α expression. Cell Death Dis 7: e2150, 2016.

25. De Vita V Jr, Hellman S, Rosenberg S and Markoe AM: Cancer: Principles and practice of oncology. Am J Clin Oncol 9: 90, 1986.

26. Birchmeier W, Hulsken J and Behrens J: E-cadherin as an invasion suppressor. Ciba Found Symp 189: 124-141, 174-176, 1995.

27. Vleminckx K, Vakaet L Jr, Mareel M, Fiers W and van Roy F: Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 66: 107-119, 1991.

28. Cano A, Pérez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, Portillo F and Nieto MA: The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2: 76-83, 2000.

29. Batlle E, Sancho E, Franci C, Domínguez D, Monfar M, Baulida J and García De Herreros A: The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol 2: 84-89, 2000.

30. Comijn J, Berx G, Vermassen P, Verschueren K, van Grunsven L, Bruyneel E, Mareel M, Huylenbroeck D and van Roy F: The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol Cell 7: 1267-1278, 2001.

31. Woodhouse EC, Chuaqui RF and Liotta LA: General mechanisms of metastasis. Cancer 80 (Suppl 8): 1529-1537, 1997.

32. Zhang W, Feng M, Zheng G, Chen Y, Wang X, Pen B, Yin J, Yu Y and He Z: Chemoresistance to 5-fluorouracil induces epithelial-mesenchymal transition via up-regulation of Snail in MCF7 human breast cancer cells. Biochem Biophys Res Commun 417: 679-685, 2012.

33. Jun HJ, Ahn MJ, Kim HS, Yi SY, Han J, Lee SK, Ahn YC, Jeong HS, Son YI, Baek JH, et al: ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. Br J Cancer 99: 167-172, 2008.

34. McConkey DJ, Choi W, Marquis F, Martin F, Williams MB, Shah J, Svatek R, Das A, Adam L, Kamat A, et al: Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev 28: 335-344, 2009.